172 related articles for article (PubMed ID: 38378868)
1. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.
Saeed A; Park R; Pathak H; Al-Bzour AN; Dai J; Phadnis M; Al-Rajabi R; Kasi A; Baranda J; Sun W; Williamson S; Chiu YC; Osmanbeyoglu HU; Madan R; Abushukair H; Mulvaney K; Godwin AK; Saeed A
Nat Commun; 2024 Feb; 15(1):1533. PubMed ID: 38378868
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.
Saeed A; Park R; Dai J; Al-Rajabi R; Kasi A; Baranda J; Williamson S; Saeed A; Ripp J; Collins Z; Mulvaney K; Shugrue M; Firth-Braun J; Godwin AK; Madan R; Phadnis M; Sun W
Cell Rep Med; 2023 Feb; 4(2):100916. PubMed ID: 36702123
[TBL] [Abstract][Full Text] [Related]
3. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
Thibaudin M; Fumet JD; Chibaudel B; Bennouna J; Borg C; Martin-Babau J; Cohen R; Fonck M; Taieb J; Limagne E; Blanc J; Ballot E; Hampe L; Bon M; Daumoine S; Peroz M; Mananet H; Derangère V; Boidot R; Michaud HA; Laheurte C; Adotevi O; Bertaut A; Truntzer C; Ghiringhelli F
Nat Med; 2023 Aug; 29(8):2087-2098. PubMed ID: 37563240
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
Strickler JH; Rushing CN; Uronis HE; Morse MA; Niedzwiecki D; Blobe GC; Moyer AN; Bolch E; Webb R; Haley S; Hatch AJ; Altomare IP; Sherrill GB; Chang DZ; Wells JL; Hsu SD; Jia J; Zafar SY; Nixon AB; Hurwitz HI
Oncologist; 2021 Jun; 26(6):465-e917. PubMed ID: 33469991
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
Marandino L; Raggi D; Calareso G; Alessi A; Colecchia M; Martini A; Briganti A; Montorsi F; Madison R; Ross JS; Necchi A
Clin Genitourin Cancer; 2021 Oct; 19(5):457-465. PubMed ID: 34006499
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frödin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Mauro DJ; Watkins DJ
J Natl Cancer Inst; 2015 Dec; 107(12):djv258. PubMed ID: 26405092
[TBL] [Abstract][Full Text] [Related]
7. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI
BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
10. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
11. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.
Kasper S; Meiler J; Knipp H; Höhler T; Reimer P; Steinmetz T; Berger W; Linden G; Reis H; Markus P; Paul A; Dechêne A; Schumacher B; Kostbade K; Virchow I; Ting S; Worm K; Schmid KW; Herold T; Wiesweg M; Schuler M; Trarbach T
Clin Colorectal Cancer; 2020 Dec; 19(4):236-247.e6. PubMed ID: 32737003
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
Monge C; Xie C; Myojin Y; Coffman K; Hrones DM; Wang S; Hernandez JM; Wood BJ; Levy EB; Juburi I; Hewitt SM; Kleiner DE; Steinberg SM; Figg WD; Redd B; Homan P; Cam M; Ruf B; Duffy AG; Greten TF
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754451
[TBL] [Abstract][Full Text] [Related]
13. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.
Segal NH; Cercek A; Ku G; Wu AJ; Rimner A; Khalil DN; Reidy-Lagunes D; Cuaron J; Yang TJ; Weiser MR; Romesser PB; Stadler ZK; Varghese AM; Ganesh K; Yaeger R; Connell LC; Faleck D; Abou-Alfa GK; Mcauliffe KC; Vaiskauskas P; Solter ML; Ogle M; Adamow MJ; Holland A; Vedantam P; Wong P; Merghoub T; Vakiani E; Hollmann TJ; Juluru K; Chou JF; Capanu M; Erinjeri J; Solomon S; Yamada Y; Kemeny N; Crane CH; Saltz LB
Clin Cancer Res; 2021 Apr; 27(8):2200-2208. PubMed ID: 33504552
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
Jia J; Howard L; Liu Y; Starr MD; Brady JC; Niedzwiecki D; Strickler JH; Nixon AB
Cancer Chemother Pharmacol; 2022 Mar; 89(3):413-422. PubMed ID: 35171350
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
Girardi DM; Niglio SA; Mortazavi A; Nadal R; Lara P; Pal SK; Saraiya B; Cordes L; Ley L; Ortiz OS; Cadena J; Diaz C; Bagheri H; Redd B; Steinberg SM; Costello R; Chan KS; Lee MJ; Lee S; Yu Y; Gurram S; Chalfin HJ; Valera V; Figg WD; Merino M; Toubaji A; Streicher H; Wright JJ; Sharon E; Parnes HL; Ning YM; Bottaro DP; Cao L; Trepel JB; Apolo AB
Clin Cancer Res; 2022 Apr; 28(7):1353-1362. PubMed ID: 35031545
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).
Scott AJ; Basu Mallick A; Dotan E; Cohen SJ; Gold PJ; Hochster HS; Subramaniam S; Barzi A; Watts GS; Blatchford PJ; Messersmith WA
Cancer Res Commun; 2022 Oct; 2(10):1188-1196. PubMed ID: 36969746
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
19. Negative Hyperselection of Patients With
Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Berlin J; Bendell JC; Hart LL; Firdaus I; Gore I; Hermann RC; Mulcahy MF; Zalupski MM; Mackey HM; Yauch RL; Graham RA; Bray GL; Low JA
Clin Cancer Res; 2013 Jan; 19(1):258-67. PubMed ID: 23082002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
